Hoth Therapeutics' mRNA Frame Shifting Therapeutic Inhibits Tumor Growth, Animal Study Shows

Hoth Therapeutics Inc (NASDAQ: HOTH) has reported that its novel anti-cancer therapeutic demonstrated positive results in humanized mast-cell neoplasm animal models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma.
The anti-cancer therapeutic, currently in development, uses mRNA frameshifting that induces apoptosis of neoplastic mast cells and cell death in neoplastic mast cells.
Furthermore, systemic administration of the anti-cancer therapeutic in the neoplasm model showed a significant reduction in tumors and neoplastic mast cell infiltration in the treatment group compared to the vehicle control group.
There were no obvious signs of toxicity, suggesting that the novel anti-cancer therapeutic was well-tolerated.
Price Action: HOTH shares are up 4.1% at $1.52 in market trading hours Tuesday.